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Abstract
Objective—Studies of behavioral weight loss intervention in psychotic patients are sparse and its
efficacy compared to other obese patients is unknown. Therefore, we compared the effect of a
cognitive-behavioral weight loss intervention in obese subjects with psychotic disorders, other
psychiatric diagnoses and without psychiatric disorders.
Methods—12-month, naturalistic study of weekly group or individual cognitive-behavioral
weight management in 222 consecutively enrolled obese patients (body mass index (BMI):
43.7±9.6) with psychotic-spectrum disorders (PSD, n=47), other psychiatric disorders (OPD,
n=49) and no psychiatric disorder (NPD, n=126).
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Results—PSD patients had greater treatment persistence (48.9%) and longer treatment duration
(8.7±4.4 months) than OPD (22.4%, 5.4±4.3 months) and NPD (22.2%, 4.9±4.7 months) patients
(p’s<.01, number-needed-to-treat (NNT)=3). In last-observation-carried-forward analyses, PSD
patients had greater percent baseline weight loss at 12 months (5.1±9.3%) than OPD and NPD
patients (2.7±5.5% and 2.4±6.3%); greater percent BMI loss at 9 and 12 months than both groups
(p’s<.05), and greater BMI loss at 9 months (2.1±3.5) and 12 months (2.3±4.1) than NPD patients
(1.1±2.3 and 1.2±2.4). Furthermore, weight loss ≥5%, occurred in 42.6% of PSD patients vs.
18.4% and 23.0% in OPD and NPD patients (p’s<.01, NNT=5 and 6). The strongest weight loss
predictor was treatment duration (β=.51–.54, p<.001). Attrition was predicted by NPD (p=.001)
and OPD group status (p=.036), lower proportion of group sessions (p=.002), higher depression
(p=.028), and lower baseline BMI (p=0.030).
Conclusions—Psychosis-spectrum disorder patients had greater weight loss than other obese
patients. Non-adherence and depression should be targeted to enhance weight loss success.
Keywords
Obesity; Weight Management Program; Weight Loss; Attrition; Psychosis
Introduction
Obesity is a risk factor for many serious health problems, including diabetes mellitus,
coronary heart disease (CHD), hypertension, stroke, and cancer1, 2. Patients with psychotic
disorders are susceptible to developing obesity due to illness-related factors, unhealthy life
style and medication side effects3. Treatment with mood stabilizers and second-generation
antipsychotics (SGA), can lead to weight gain, obesity, and/or metabolic syndrome4–6.
Pharmacological treatment for obesity in schizophrenia patients are only modestly
effective7,8 and potential side effects and drug-drug interactions limit its utilization,
although metformin and topiramate usually do not interfere with antipsychotic drug levels.
In contrast, non-pharmacological treatments, such as cognitive-behavioral therapy, life style
modification, exercise training and nutritional counseling, are considered safe. Most non-
pharmacological weight loss studies in psychiatric patients to date had relatively short
follow-up periods7, 9, 10 and have generally included only patients with schizophrenia or
schizoaffective disorders. The efficacy of these treatment programs in patients with other
psychiatric diagnoses has not been studied. Moreover, the relative success of behavioral
weight management programs in severely mentally ill patients compared to obese without
psychiatric disorders is not known.
Studies conducted in the general population have demonstrated that more comprehensive
weight loss interventions are more successful11. For both the behavior therapy and
cognitive-behavior therapy, the effect appears to be larger when diet and/or exercise
treatments were added. A meta-analysis of 24 behavioral weight loss intervention trials in
obese, US multi-ethnic and minority adults (n=13,326) found that single and dual
component interventions had a small effect size, whereas three-component interventions
achieved a moderate effect size12. The extent to which these findings apply to treatment of
obesity in the mentally ill is not clear. One of the few studies in this area found higher
attrition from a behavioral weight management program among obese subjects with
comorbid mental disorders at 6 months13. Conversely, results regarding baseline depression
as a moderating variable of weight loss success at 6 and 12 months have been
inconclusive14, 15.
In the present study, we aimed to examine whether a cognitive-behavioral weight
management program is effective in obese patients with psychotic disorders in a 12-month
naturalistic prospective trial. We further aimed to test whether patients with psychotic
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disorders were able to lose as much weight as obese patients without major psychotic
disorders or those without any psychiatric illness.
Methods
Setting and Subjects
This was a 12-month, naturalistic, prospective cohort study conducted in an integrated
clinical weight management program. Patients were recruited consecutively at the Center for
Weight Management of the North Shore-Long Island Jewish Health System, New Hyde
Park, NY, between 2003 and 2005, for long-term group or individual cognitive-behavior
therapy as well as nutrition and exercise physiology services. Patients were either self-
referred or referred by other healthcare professionals. Patients' insurance, either Medicaid or
Medicare, paid for the weight management program. All patients who enrolled in the weight
management program agreed to participate in the study. Weight and BMI data were
collected prospectively as part of general clinical treatment. The study was approved by the
North Shore-Long Island Jewish Medical Center Institutional Review Board, Manhasset,
NY.
The subjects were divided into three groups: patients with psychotic spectrum disorders;
patients with other psychiatric disorders; and patients without a classifiable psychiatric
disorder. Eating Disorder, Not Otherwise Specified, was not used in this categorization and
is reported separately per group. The grouping was based on subjects’ DSM-IV diagnoses
from chart review. Schizophrenia, affective disorders with psychotic features, and psychosis
NOS were classified as psychotic spectrum disorders.
Assessments
Prior to the initial session, patients were mailed a comprehensive questionnaire that covered
information about demographic variables, psychiatric illness, psychological functioning,
sleep apnea, binge eating behaviors, weight loss history, exercise and nutrition behavior, and
quality of life, the Depression Inventory (BDI)16, SCL-9017, the Satisfaction with Life Scale
(SLS)18, and the Borderline Syndrome Index (BSI)19. The psychiatric diagnoses and
treatments were established by clinical interview and review of medical records at intake.
Interventions
The treatment consisted of cognitive behavior therapy from the Northwestern University
Medical School’s People at Risk Weight Control Program20. Weekly treatment was
delivered by a team consisting of psychotherapists, a nutritionist, and an exercise
physiologist in individual sessions, lasting 45–50 minutes, and group sessions, lasting 60–75
minutes. The assignment of group or individual treatment was based on clinical judgment
and consideration of patient preference. The treatment provided enhanced self monitoring of
food intake and exercise habits, behavioral contracting, cognitive restructuring, and stimulus
control. The same treatment was delivered to all three diagnostic groups. Group sessions
were composed of patients with and without psychotic spectrum disorders separately. There
were no differences in how patient groups paid for treatment services.
Outcome Measures
The primary outcome measures were the absolute and relative change in weight and body
mass index (BMI). Measurement of height and weight were taken during the intake visit,
and weight was measured during weekly follow-up sessions. BMI was calculated as weight
in kilogram divided by squared height in meter (kg/m2). Secondary outcome measures
included percentage of patients with ≥5% weight loss at the end of treatment and treatment
persistence, defined as staying in treatment, as opposed to dropping out.
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Statistical Analyses
The three groups were compared across demographic and clinical variables using chi-square
test and t-test for categorical and continuous variables, respectively. The outcome variables
were examined at 3, 6, 9 and 12 months of treatment after baseline. For within-group effects
of the change from baseline to endpoint, we calculated the effect size as Cohen’s d21, as well
as their 95% confidence intervals. Analysis of variance was used to test the differences in
outcome variables among the three groups. Multivariate regression analysis was conducted
to identify baseline variables that were moderators22 of change in BMI that utilized all
factors from prior univariate analyses with a significance level of p<0.10 plus age, race, and
sex. The p value of <0.10 was only used to select baseline variables that were moderators of
change in BMI as a pre-requisite for the multivariate analyses. All final results were
significant only if p<0.05. To deal with attrition, both the last observation carried forward
(LOCF) and mixed modeling of repeated measures methods were used. Since results were
similar, we only present LOCF results. We analyzed “all-completers” (i.e., patients with data
at each of the four 3-montly time intervals), and compared their data with the LOCF results.
Retention in the program was assessed using Kaplan-Meier survival analysis and Cox
regression. Statistical analyses were conducted using the SPSS version 17.0 (SPSS Inc,
Chicago, IL).
Results
The 222 subjects in this study were 49.2±14.1 years old with BMI of 43.7±9.6. Forty-seven
(21.2%) had psychotic disorders, 49 (22.1%) had other psychiatric disorders, and 126
(56.8%) had no psychiatric disorders. Patients with psychotic disorders had lower
educational levels, were less likely to be employed and had a lower general assessment of
function score than the other two groups.
Treatment Persistence
At the 12-month follow-up, 62 patients (27.9%) remained in treatment. Patients with
psychotic disorders had significantly greater persistence (48.9%) and a longer treatment
duration (8.7±4.4 months) than patients with other psychiatric disorders (22.4%, 5.4±4.3
months) and subjects without mental illness (22.2%, 4.9±4.7 months) (p’s<.01, number-
needed-to-treat (NNT)=3). Figures 1 shows the Kaplan-Meyer survival curves for treatment
persistence. Median treatment duration until drop-out was 11.5, 4.2, and 3.0 months for the
three groups (Log Rank test=18.22, p<0.001).
Body Weight and Body Mass Index Changes
The entire sample lost 3.54±9.02 lbs from baseline (i.e., 1.34±3.39% loss of baseline
weight) at the 3-month follow-up, 6.27±14.62 lbs (2.33±5.22%) at 6 months, 7.98±17.21 lbs
(2.96±6.23%) at 9 months, and 8.47±18.75 lbs (3.15±6.70%) lbs at 12 months (p<.001)
(Figures 2a–2b).
In observed cases, study groups did not differ regarding absolute or relative decrease in
weight at any time point (Figures 2a). In the LOCF analyses there was no statistically
significant difference in absolute weight loss among the three groups at 12-month follow-up,
i.e., 13.17±24.21 lbs (ES=0.24, 95% CI:0.11–0.37) in the psychotic disorders group, as
compared with 7.67±21.22 lbs ( ES=0.16, 95% CI:0.04–0.29) in the non-psychotic
psychiatric group and 7.02±14.92 lbs ( ES=0.21, 95%CI:0.13–0.29) in the group without
psychiatric disorders. However, the psychotic disorders group had significantly greater
decreases in percent baseline weight at 12-month follow-up (5.1±9.3%) compared to the
other two groups (2.7±5.5% and 2.4±6.3%, p=0.032 and p=0.048, respectively) (Figure 2b).
The Group x Time interaction was significant in repeated measures ANOVA (p=0.002). The
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results of BMI changes (Figures 3a–3b) were similar to those of body weight changes
reported above (Figures 2a–2b).
The LOCF analysis showed that at the 12-month follow-up, 42.6% of patients from the
psychotic disorders group lost ≥5% body weight compared to 18.4% in the group with non-
psychotic psychiatric disorders and 23.0% in subjects without mental illness (p’s<.01,
NNT=5 and 6)). The odds ratio for the psychotic group to lose ≥5% body weight was 2.48
(95%CI: 1.22–5.05, p=0.014) compared to the non-psychotic patients and 3.29 (95%CI:
1.32–8.18, p=0.004) compared to the non-psychiatric patients.
Predictors of BMI Reduction
Baseline demographic and clinical characteristics as well as treatment duration were used to
predict change in BMI in separate LOCF multiple regression analyses. The results were
similar whether the outcome was absolute or relative BMI change from baseline. When
treatment duration was not included in the model, patient group was the most significant
predictor of absolute weight loss, with the psychotic group improving their BMI more than
each of the other two groups (p=.007 and p=.003, respectively). In all groups, treatment
duration was the most significant predictor of weight loss (β’s=.51–.54, p<0.001). The only
additional predictor of weight loss that was consistently significant in all outcome variables
in multiple regression analyses was the past number of times patients had lost >20 lbs.
Taking weight gain producing medications at baseline predicted lower absolute and relative
BMI reductions, but the medication variable dropped out of the final models for weight
change.
Predictors of Treatment Persistence
A Cox regression analysis was conducted with univariate baseline characteristics at a
significance level of <0.10 and four variables remained significant in the final model of
earlier dropout (chi-square=37.17, df=5, p<.001): non-psychotic group status (hazard
ratio=2.29, p=0.001) or non-psychiatric group status (hazard ratio=1.81, p=0.036), higher
baseline Beck Depression Inventory score (hazard ratio=1.02, p=.028), lower baseline BMI
(hazard ratio=.98, p=0.030), and greater proportion of group sessions (hazard ratio=.99,
p=0.002).
Discussion
We examined whether a 12-month, multi-component, mixed group and individual cognitive
behavior weight management program was effective in a consecutively enrolled obese
patient cohort with psychotic disorders and compared the efficacy to the outcomes in
patients with other psychiatric diagnoses and subjects without mental illness. The results
showed that patients with psychotic disorders had superior weight and BMI outcomes than
the other two groups in LOCF analyses. The NNT for losing at least 5% of baseline body
weight was 5–6. Patients with psychotic disorders had better treatment adherence, resulting
in longer treatment exposure (approximately 9 months vs 5 months) than patients in the
other two groups, and the NNT for remaining in treatment at 1 year was 3. The significance
of treatment duration as a mediator of weight reduction was confirmed by the multiple
regression analyses. Of interest is also the fact that in all treatment groups a higher severity
of depressive state, assessed with the Beck Depression Inventory, predicted shorter
treatment duration.
To our knowledge, this is the first study to compare weight loss outcomes of a non-
pharmacological treatment program between patients with psychotic disorders and
individuals with non-psychotic psychiatric conditions or no psychiatric illness at all.
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Previous studies examined weight loss interventions for patients with schizophrenia or
patients taking antipsychotic medications5, 6, 9, 10, 23–27, or, separately, in the general obese
population11–15. Although non-pharmacological interventions have been shown to help
patients with schizophrenia and those treated with antipsychotics lose weight, subjects
enrolled in these trials were likely to be quite motivated, as they were consenting to intense
monitoring in a structured research program. Thus, it is relatively unknown how these
intervention programs perform in psychiatrically ill patients treated in real-world,
naturalistic settings.
Our study showed significant weight loss in a 12-month program delivered in a real-world,
naturalistic setting, regardless of patient diagnosis and medication treatment. The magnitude
of weight loss was comparable or larger than in previous studies. Menza et al26 reported on
a similar study, and their 12-month data showed that patients lost 6.6 lbs in average (3.0% of
baseline body weight) with a 1.7 BMI unit decrease. In the Brar et al24 study, patients in the
behavioral treatment group lost 2.0 kg (about 4.4 lbs, 2.0% of baseline body weight) at the
end of 14-week treatment. In contrast, patients in the present study lost about 5.23 lbs
(1.98% of body weight) at 3- months and 20.01 lbs (7.92% of body weight) at 12-month
treatment. Even with the conservative LOCF analysis, our sample still lost 8.47 lbs on
average (3.15% of body weight) at 12-months. However, the effect sizes in our study were
somewhat smaller than those reported for obese patients in the general population
consenting to a structured weight loss program11, 12 in that the effect sizes were between
0.16 and 0.24 for weight loss and 0.12 and 0.29 for BMI reduction, which was comparable
only to the dual intervention program in obese patients, which had an average effect size of
0.22 in a previous meta-analysis12. By contrast, three-component interventions resulted in an
average effect size of 0.52 in general population samples, but these were selected to consent
to an intensive treatment program.
In observed cases, we found a BMI reduction of 3.58 at 12 months. Based on studies that
reported a 1 point reduction in BMI to be associated with an 8% reduction in coronary heart
disease (CHD) risk 28, patients in our sample achieved an estimated average 28% CHD risk
reduction after 1 year of treatment.
A clinically important finding of the study is that patients with psychotic disorders, such as
schizophrenia and bipolar disorder, were able to lose as much weight when receiving a
multi-component weight loss intervention, if not more, as other obese patients, and did so by
staying in treatment longer. Almost half of the psychotic disorder group patients stayed in
treatment for 12 months, compared to less than 25% of the other patients, leading to the
superior weight outcome for this patient group at LOCF endpoint, as treatment duration was
the most significant predictor of weight loss, regardless of psychiatric diagnosis and
psychotropic treatment. This is consistent with the all-completer analysis, showing that
patients who stayed in treatment for 12 months in all three groups lost similar amount of
weight. This finding underscores that treatment adherence is a key factor for the success of a
weight management program, as has also been shown in the general obese population where
higher treatment intensity was associated with better outcomes11. This finding is further
consistent with a recent report that in a naturalistic treatment setting, the only correlate of
weight loss in a sample of 113 severely mentally ill patients was the number of attended
treatment sessions29.
Another relevant result in our study is that the severity of depressive symptoms at baseline
was associated with shorter treatment duration. Although this finding needs to be replicated,
it may suggest that depression interferes with treatment adherence and that, in turn, treating
depression might improve treatment engagement and persistence. Findings in the general
obese population have been inconclusive so far, but have, to our knowledge, not focused on
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the relationship of depression with treatment adherence, but rather with weight loss. While
in a Portuguese study, pre-treatment depression was not a significant moderating variable14,
a large US study of 1172 female and 460 male obese patients found that baseline depression
predicted less weight loss success in females, but not in males15. In addition, in our
multivariate model, lower baseline BMI was also related to greater attrition, suggesting that
those with less severe obesity may have had less motivation to remain in treatment. In the
same context, in our second multiple regression analysis, the degree of BMI reduction was
significantly associated with the number of past weight loss attempts resulting in >20 lbs
weight reduction in addition to psychotic disorder group status and treatment duration. This
result appears to be consistent with observations in the general obese population where
unrealistic weight loss expectations were associated with greater dropout rates over a 12
month period, especially in the first 6 months. For example, in an Italian sample of 1785
help seeking, middle aged, obese subjects, each expected BMI unit decrease increased the
drop out by 12%30. Thus, patients who already had the experience that they could lose a
considerable amount of weight might be more realistic in their goal-setting and might also
get less easily discouraged by a slow progress or times of little success. Finally, in contrast
with previous findings in the general obese population,16 individual sessions were not more
effective than group sessions for BMI loss, as we found that a greater proportion of group
treatment sessions was associated with longer treatment duration. We acknowledge,
however, that a selection bias could explain in part our finding, in that patients who were
perceived to be more difficult to treat and engage with might preferentially have been
assigned to individual treatment.
Our findings need to be interpreted within the limitations of our naturalistic study, which
allowed the comparison of a cognitive behavioral weight loss intervention in three different
patient populations. A major limitation of the study is the lack of randomization, the lack of
blindness, and the possibility that patients with psychotic spectrum disorders received more
clinical attention, resulting in them staying in the program longer, which in turn played a
role in their greater weight loss. However, it is actually not possible to randomize by group
as they are distinct and the same treatment was delivered by the same personnel in the same
setting. Moreover, blinding was not needed as the same treatment was delivered. While the
outcome could have been blinded, the outcome was an objective measure, i.e., weight
change. Nevertheless, we cannot exclude that PSD patients received more attention, which
might have mediated the results. However, the objectives of this study were not to identify
mediators and moderators of weight change; these analyses were all secondary and
hypothesis generating. The primary outcome of our study is that PSD patients referred to a
weight management program are at least as likely under regular clinical conditions to benefit
from such a program as patients who neither have a psychotic-spectrum disorder not take
medications known to increase (and maintain abnormally elevated) weight. Furthermore, the
treatment retention rate was low, only 48.9% for the PSD group and about 22% for the other
two groups at one year. Thus, data from the study need to be interpreted with caution.
However, these retention rates were similar to those from other real-world observational
studies. In addition, we did not have sufficient data to assess changes in antipsychotic and
mood stabilizer medications during the study, but it is likely that clinicians referred patients
after they attempted medication adjustments. Moreover, we did not have metabolic data to
evaluate downstream effects of weight loss, and could not assess dietary restraint and
behavioral disinhibition, which have been associated with weight loss results in the general
obese population30. Finally, we did not have data on the persistence of weight loss after
treatment discontinuation beyond the 1-year study period or on patients who dropped out the
study. Such data should be collected in psychiatrically ill patients to identify high-risk
patients in whom longer treatment and/or refresher interventions might be beneficial.
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In summary, a multimodal cognitive behavior weight management program was useful in
helping obese patients lose weight, regardless of psychiatric diagnosis and psychotropic
treatment. Although we cannot exclude a potential selection bias of more adherent
psychiatrically ill patients, these data should counter the behavioral weight management
nihilism that many treating clinicians seem to have adopted. More research is needed to
adapt weight management strategies to also reach less motivated patient groups. Our data
further suggest that improving adherence, setting realistic expectations, and addressing
depression could enhance weight management treatment success in the obese. Further
studies focusing on these aspects are needed to facilitate the development and
implementation of successful weight management programs that can be applied to a broad
array of clinical settings.
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Figure 1.
Kaplan-Meier survival curves for the three patient groups. (PSD = Psychosis Spectrum
Disorders, OPD = Other Psychiatric Disorders, NPD = No Psychiatric Disorders)
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Figure 2.
Figure 2a. Weight loss for observed cases at each time point: Percent weight change from
baseline.
Note: The numbers in the legend are the sample sizes for the three groups. PSD = Psychosis
Spectrum Disorders, OPD = Other Psychiatric Disorders, NPD = No Psychiatric Disorders.
The numbers inside the bars are the sample sizes for the group at each time point. AC at 12
mos = All Completers, ie., cases whose weight data are available for baseline and all four
follow-up time points. Error bars represent standard errors. No significant differences among
the groups at any time point.
Figure 2b. Weight loss for all cases (LOCF) at each time point: Percent weight change from
baseline.
Note: PSD = Psychosis Spectrum Disorders, OPD = Other Psychiatric Disorders, NPD = No
Psychiatric Disorders. There were no significant differences among the three groups at 3
months and 6 months. At 9 months, PSD was marginally significant than the other two
groups, p’s = .05–.10. At 12 months, PSD lost significantly more weight than the other two
groups, p’s = .032 and .048.
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Figure 3.
Figure 3a. Weight loss for observed cases at each time point: Percent BMI change from
baseline.
Note: The numbers in the legend are the sample sizes for the three groups. PSD = Psychosis
Spectrum Disorders, OPD = Other Psychiatric Disorders, NPD = No Psychiatric Disorders.
The numbers inside the bars are the sample sizes for the group at each time point. AC at 12
mos = All Completers, ie., cases whose weight data are available for baseline and all four
follow-up time points. Error bars represent standard errors. No significant differences among
the groups at any time point.
Figure 3b. Weight loss for all cases (LOCF) at each time point: Percent BMI change from
baseline.
Note: PSD = Psychosis Spectrum Disorders, OPD = Other Psychiatric Disorders, NPD = No
Psychiatric Disorders. There were no significant differences among the three groups at 3
months and 6 months. At 9 months, PSD was significant than the other two groups, p’s = .
035 and .046. At 12 months, PSD was significant than the other two groups, p’s = .019 and .
028.
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